UNSPSC 51314343: Chlorpheniramine/guaifenesin/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314343 Chlorpheniramine/guaifenesin/pseudoephedrine is a Commodity code that covers specific pharmaceutical combination products, but the recent state and local opportunities posted under this code show substantial scope misalignment. The Seminole County, Florida procurement tags an IFB for naloxone and drug deactivation systems — products unrelated to the chlorpheniramine/guaifenesin/pseudoephedrine combination. The Texas Health and Human Services Commission's RFI explores direct-to-manufacturer prescription programs without naming specific drug products. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP addresses generic multi-source pharmaceuticals and OTC products broadly, encompassing many therapeutic classes but not specifically the chlorpheniramine/guaifenesin/pseudoephedrine combination named in the code. The code shows little relevant recent activity; issuing bodies when procurement does occur include state health and human services departments, county health agencies, and multistate cooperative purchasing vehicles coordinating demand across participating jurisdictions.

The geographic spread reflects activity in Florida, Texas, and Minnesota through MMCAP's multistate participation. The Seminole County IFB (due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through electronic bidding with quarterly deliveries. The Texas HHS Commission's RFI (response deadline April 3, 2026) gathered vendor capability information on direct contracting models outside traditional pharmacy benefit manager and group purchasing organization arrangements. The MMCAP RFP (due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products effective July 1, 2026, with wholesaler distribution through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson. None of these opportunities explicitly solicited the specific chlorpheniramine/guaifenesin/pseudoephedrine combination, suggesting the code does not currently match active state and local demand for this particular therapeutic category.